Literature DB >> 20535635

A different interaction between parathyroid hormone, calcitriol and serum aluminum in chronic kidney disease; a pilot study.

Fatih Mehmet Azik1, Mesiha Ekim, Onur Sakallioglu, Ahmet Aydin.   

Abstract

BACKGROUND/AIMS: Aluminum (Al) is an ingredient of a variety of foodstuffs and medications as well as of domestic water supplies. The patients with chronic kidney disease (CKD) are more susceptible to bone toxicity of Al. The aim of the study was to investigate the interactions between serum Al, parathyroid hormone (PTH) and active vitamin-D in CKD.
METHODS: A total of 10 pediatric patients with CKD and 20 healthy controls were enrolled in study. The blood calcium, aluminum, PTH, alkaline phosphatase and phosphorus were evaluated at onset and following a regimen of oral 1,25 dihydroxycholecalciferol (1,25 DHC) for 4 weeks.
RESULTS: Although median values of PTH, calcium, phosphorus and alkaline phosphatase did not differ (P > 0.05) after calcitriol administration, the aluminum levels (median: 27.2 ng/ml, range: 11.3-175) declined significantly (median: 3.8 ng/ml, range: 0.64-11.9) after a regimen of oral 1,25 DHC for 4 weeks in all participants (P < 0.05). The median levels of aluminum after 1,25 DHC did not show statistically significant difference with median aluminum levels of healthy controls (median: 2.5 ng/ml, range: 0.2-33.2) (P < 0.05).
CONCLUSION: Calcitriol may lead to decline in serum Al levels in CKD patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20535635     DOI: 10.1007/s11255-010-9784-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  17 in total

Review 1.  Aluminium toxicokinetics: an updated minireview.

Authors:  R A Yokel; P J McNamara
Journal:  Pharmacol Toxicol       Date:  2001-04

Review 2.  Adynamic bone revisited: is there progress?

Authors:  Cheryl P Sanchez
Journal:  Perit Dial Int       Date:  2006 Jan-Feb       Impact factor: 1.756

Review 3.  Aluminum: toxin or innocent bystander in renal osteodystrophy.

Authors:  H H Malluche; M C Faugere
Journal:  Am J Kidney Dis       Date:  1985-11       Impact factor: 8.860

4.  Aluminum metabolism in rats: effects of vitamin D, dihydrotachysterol, 1,25-dihydroxyvitamin D and phosphate binders.

Authors:  J C Chan; M Jacob; S Brown; J Savory; M R Wills
Journal:  Nephron       Date:  1988       Impact factor: 2.847

5.  Organ distribution of aluminium in uremic rats: influence of parathyroid hormone and 1,25-dihydroxyvitamin D3.

Authors:  R Hirschberg; D von Herrath; R Voss; W Bossaller; U Mauelshagen; A Pauls; K Schaefer
Journal:  Miner Electrolyte Metab       Date:  1985

6.  Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients.

Authors:  Y Pei; G Hercz; C Greenwood; D Sherrard; G Segre; A Manuel; C Saiphoo; S Fenton
Journal:  Kidney Int       Date:  1992-05       Impact factor: 10.612

Review 7.  Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy.

Authors:  Joel D Hernandez; Katherine Wesseling; Isidro B Salusky
Journal:  Semin Dial       Date:  2005 Jul-Aug       Impact factor: 3.455

8.  Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis.

Authors:  Marcela Avila-Díaz; Mario Matos; Elvia García-López; María-del-Carmen Prado; Florencia Castro-Vázquez; María-de-Jesús Ventura; Elia González; Dante Amato; Ramón Paniagua
Journal:  Perit Dial Int       Date:  2006 Jan-Feb       Impact factor: 1.756

9.  Metabolism and toxicity of aluminum in renal failure.

Authors:  A C Alfrey; A Hegg; P Craswell
Journal:  Am J Clin Nutr       Date:  1980-07       Impact factor: 7.045

10.  Osteomalacia in chronic renal failure: a syndrome previously reported only with maintenance dialysis.

Authors:  A J Felsenfeld; R A Gutman; F Llach; J M Harrelson
Journal:  Am J Nephrol       Date:  1982       Impact factor: 3.754

View more
  2 in total

Review 1.  Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.

Authors:  Calvin C Willhite; Nataliya A Karyakina; Robert A Yokel; Nagarajkumar Yenugadhati; Thomas M Wisniewski; Ian M F Arnold; Franco Momoli; Daniel Krewski
Journal:  Crit Rev Toxicol       Date:  2014-10       Impact factor: 5.635

2.  Association of low serum aluminum level with mortality in hemodialysis patients.

Authors:  Ching-Wei Hsu; Cheng-Hao Weng; Cheng-Chia Lee; Dan-Tzu Lin-Tan; Kuan-Hsing Chen; Tzung-Hai Yen; Wen-Hung Huang
Journal:  Ther Clin Risk Manag       Date:  2016-09-14       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.